Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Objective: This network meta‐analysis evaluates the efficacy and safety of tirzepatide compared to glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and other weight loss drugs in the treatment of overweight and obesity. Methods: MEDLINE, Embase, and Cochrane CENTRAL were searched for randomized controlled trials on tirzepatide, GLP‐1 RA, and weight loss drugs approved by the US Food and Drug Administration. A network meta‐analysis was performed, drawing direct and indirect comparisons between treatment groups. Network diagrams and surface under the cumulative ranking curve analysis were performed for primary (≥5%, ≥10%, ≥15%, absolute weight loss) and secondary outcomes and adverse effects. Results: Thirty‐one randomized controlled trials, involving more than 35,000 patients, were included in this study. Tirzepatide 15 mg ranked in the top three across weight‐related parameters, glycemic profile (glycated hemoglobin), lipid parameters (total cholesterol, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, triglycerides), and blood pressure. Tirzepatide 15 mg had the highest efficacy compared with placebo for achieving ≥15% weight loss (risk ratio 10.24, 95% CI: 6.42–16.34). As compared to placebo, tirzepatide and GLP‐1 RA across all doses had significant increases in gastrointestinal adverse effects. Conclusions: The superiority of tirzepatide and GLP‐1 RA in inducing weight loss and their ability to target multiple metabolic parameters render them promising candidates in the treatment of patients with overweight and obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · cited 1×
“When continuous variables in means and standard deviations were not provided, they were derived from their respective medians and interquartile ranges using formulas devised by Wan et al. [26].”
MethodOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“3.0% to 8.6%, with significant adverse side effects [66, 70, 71].”
BackgroundInfluentialSalanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 1×
“To analyze the validity of the indirect comparisons, consistency was measured using local nodes splitting and Wald testing [33 – 35].”
MethodDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · cited 1×
“The use of medications such as liraglutide, semaglutide, and tirze-patide is aligned with the 2022 guidance of the American Diabetes Association and the European Association for the Study of Diabetes, which has made weight loss a priority in patients with T2DM [78].”
BackgroundTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Research works printed but not linked: 35
- 10.1016/j.metabol.2018.09.005 · DOI · Paper page
- 10.1093/ajcn/72.3.694 · DOI · Paper page
- 10.1136/bmjgh‐2022‐009773 · DOI · Paper page
- World Obesity, 2023, World Obesity Atlas 2023
- Lobstein T, World Obesity Atlas 2022
- 10.1016/j.eprac.2022.10.006 · DOI
- 10.1038/s41430‐020‐0610‐y · DOI
- 10.1046/j.1365‐2125.2001.01294.x · DOI
- 10.1900/RDS.2014.11.202 · doi:10.1900/rds.2014.11.202
- 10.7570/jomes22012 · DOI
- 10.1371/journal.pone.0285197 · DOI · Paper page
- 10.1016/S0140‐6736(03)15268‐3 · DOI · Paper page
- 10.1002/jrsm.1058 · DOI · Paper page
- 10.1002/sim.6236 · DOI · Paper page
- 10.1002/jrsm.1143 · DOI
- 10.1002/sim.8158 · DOI · Paper page
- 10.18549/PharmPract.2017.01.943 · DOI · Paper page
- 10.3945/ajcn.111.024927 · DOI · Paper page
- 10.1016/S0140‐6736(10)60888‐4 · DOI · Paper page
- 10.1038/oby.2009.155 · DOI · Paper page
- 10.1016/S0140‐6736(18)31773‐2 · DOI · Paper page
- 10.2337/dc13‐0354 · DOI
- 10.1001/jama.2021.3224 · DOI · Paper page
- 10.1016/S0140‐6736(23)01200‐X · DOI · Paper page
- 10.2165/00002018‐200831010‐00005 · DOI · Paper page
- 10.3390/ph14100991 · DOI · Paper page
- 10.1161/CIRCRESAHA.116.307591 · DOI · Paper page
- 10.3389/fphar.2022.998816 · DOI
- 10.3389/fcvm.2021.768119 · DOI · Paper page
- 10.1016/S0140‐6736(15)00803‐X · DOI · Paper page
- 10.1016/S2213‐8587(22)00070‐5 · DOI · Paper page
- 10.23876/j.krcp.22.001 · DOI
- 10.1111/j.1755‐5949.2010.00172.x · DOI · Paper page
- 10.5414/CP202135 · DOI
- 10.1111/j.1463‐1326.2010.01242.x · DOI · Paper page
Cited by
Global burden of cardiovascular diseases: projections from 2025 to 2050
Chong, B., Jayabaskaran, J., Jauhari, S. M., Chan, S. P., Goh, R., Kueh, M. T. W., Li, H., Chin, Y. H., Kong, G., Anand, V. V., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae281 · Cited by 793
Self-citationObesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists
Barrett, T. S., Hafermann, J. O., Richards, S., LeJeune, K., & Eid, G. M. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.3590 · Cited by 87
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Old, V. J., Davies, M. J., Papamargaritis, D., Choudhary, P., & Watson, E. L. (2025) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13677 · Cited by 55
Metadata
- Authors
- Pan, X., Tan, B., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M., Khoo, C. M., Mehta, A., Majety, P., Grandhi, G. R., Dimitriadis, G. K., Foo, R., Chew, N. W. S., Le Roux, C. W., Mamas, M. A., & Chan, M. Y.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2024-02-27
- Volume
- 32
- Issue
- 5
- Pages
- 840-856
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W4392772523
- Cited by
- 71
- References
- 59
- FWCI
- 16.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis. https://app.cochat.ai/papers/10.1002/oby.24002
- The paper
- Pan, X., Tan, B., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M., Khoo, C. M., Mehta, A., Majety, P., Grandhi, G. R., Dimitriadis, G. K., Foo, R., Chew, N. W. S., Le Roux, C. W., Mamas, M. A., & Chan, M. Y. (2024). Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis. Obesity. https://doi.org/10.1002/oby.24002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.